Cellspect Co., Ltd of Morioka-City, Iwate at MEDICA 2018 in Düsseldorf -- MEDICA - World Forum for Medicine

Cellspect Co., Ltd

Morioka New Technology Business Creation, Support Center, 1-10-82, Kitaiioka, 020-0857 Morioka-City, Iwate
Japan
Telephone 81 19 6816710
Fax 81 19 9030418
sales@cellspect.com

This company is main exhibitor of

Hall map

MEDICA 2018 hall map (Hall 18): stand B10

Fairground map

MEDICA 2018 fairground map: Hall 18

Our range of products

Our products

Product category: Rapid tests in clinical chemistry

Development of diagnostic equipment suitable for the next generation type of point of care testing kit

Many clinical sites are now handling large volumes of specimens by large-scale automatic inspection equipment. Therefore, it takes time to show the inspection value and conclude results for each person. To avoid this problem, in recent years, a small clinical testing device termed Point Of Care Testing Kit (POCT: inspection at places where healthcare is carried out) is getting popular. However, it is difficult for POCTs to give highly accurate inspection values due to technical limitations. Most POCTs are limited to show ON / OFF (positive / negative) diagnosis only.
The POCT which we are developing is using various image processing technology, formulation technology, and material physics technology for detection based either on biochemical or on immunological principles, making it possible to measure the inspection sticks accurately and simultaneously (patent pending).
With our POCTs, we achieved multiple examinations simultaneously and easily, and moreover, these POCTs work without limitation of time and places. These POCTs are highly promising in fields requiring promptness such as visiting medicine, emergency medical care, and telemedicine.

More Less

Product category: Rapid tests in clinical chemistry

Development of non-invasive diagnostic probe that can be applied for the diagnosis and prognosis of endometriosis progression

Endometriosis affects about 10% of women with menstrual cycle and about 1% of patients with chocolate cysts grow ovarian cancer. Diagnosis of tumorgenesis of chocolate cyst depends on the pathological examination of the excised tissue. Many patients with chocolate cysts are not cancerized, considering the possibility of tumorgenesis in the future, however, are suggested surgical removal of the cyst in many cases. Thus, it is expected to put into practice using a diagnostic method with less invasion and higher accuracy. Recently, by collaborating with Department of Obstetrics & Gynecology, Nara Medical University, we discovered an iron complex in living body as a biomarker. By detecting this biomarker in chocolate cystic fluid, we can determine the degree of malignancy (cancer, non-cancer). We further developed a minimally invasive transvaginal probe (sensor) for clinical detection of this biomarker. Japanese Patent No. 6078687

More Less

About us

Company details

FOR THE NEW ERA OF MEDICINE

CREATION
We develope new technologies for healthcare
FUSION
We integrate new technologies with existing ones
PASSION
We devote all our passion

More Less